Table 1.
Baseline demographics and neurological disease characteristics.
| Demographics | Disease characteristics | DMT use | |||
|---|---|---|---|---|---|
| Age, mean [SD], y | 49.3 [12.2] | Disease duration, mean [SD], y | 13.1 [9.6] | Anti-CD20, n (%) | 54 (48.6) |
| Sex, n (% female) | 85 (76.6) | EDSS, median [range] | 2.5 [0, 8.5] | Natalizumab, n (%) | 3 (2.7) |
| Race, n (% white) | 80 (72.1) | Disease type | Fingolimod, n (%) | 9 (8.1) | |
| Hypertension, n (%) | 23 (20.7) | RRMS, n (%) | 72 (64.9) | Dimethyl fumarate, n (%) | 6 (5.4) |
| Diabetes, n (%) | 23 (20.7) | SPMS, n (%) | 21 (18.9) | Teriflunomide, n (%) | 4 (3.6) |
| Asthma or COPD, n (%) | 7 (6.3) | PPMS, n (%) | 8 (7.2) | Glatiramer, n (%) | 10 (9) |
| Former or current cigarette use, n (%) | 11 (9.9) | CIS, n (%) | 2 (1.8) | Interferon beta, n (%) | 2 (1.8) |
| Related disorders, n (%) | 8 (7.2) | Other therapies, n (%)⁎⁎ | 3 (2.7) | ||
| NMOSD | 4 | None | 20 (18) | ||
| MOGAD | 1 | ||||
| Other* | 3 | ||||
Definitions: CIS = clinically isolated syndrome, COPD = chronic obstructive pulmonary disease, MOGAD = myelin oligodendrocyte glycoprotein associated disease, NMOSD = neuromyelitis optica spectrum disorder, PPMS = primary progressive MS, RRMS = relapsing remitting MS, SPMS = secondary progressive MS.
Legend: Table 1 shows demographic data and neurological disease characteristics of our cohort.
Other related disorders included 1 patient with Neuro Behcet's, 1 patient with tumor necrosis factor (TNF) exposure-related demyelination, and 1 patient with a single demyelinating brainstem lesion.
Other therapies: Intravenous immune globulin and anti-CD20 therapy combination (1), chronic monthly high-dose steroid infusions (1), glatiramer and chronic monthly high-dose steroid infusions combination (1).